FACC

MedAxiom, Wharton Online Expand Partnership to Shape Future Cardiovascular Business Leaders

Retrieved on: 
Thursday, September 7, 2023
Education, Health, Continuing, Cardiology, Training, University, Online, Curriculum, FACC, Student, Partnership, MBA, MD, Economics, Management

MedAxiom, the cardiovascular community’s premier destination for organizational performance solutions, has expanded its partnership with Wharton Online to develop a first-of its-kind business and management program designed specifically for cardiovascular fellows and early careerists.

Key Points: 
  • MedAxiom, the cardiovascular community’s premier destination for organizational performance solutions, has expanded its partnership with Wharton Online to develop a first-of its-kind business and management program designed specifically for cardiovascular fellows and early careerists.
  • The program delivers world-class education from top business leaders to close the knowledge gap and empower the next generation of cardiovascular professionals.
  • “MedAxiom is committed to building cardiovascular leaders of the future.”
    The self-paced online program offers lecture videos, quizzes and activities designed specifically for fellows to jumpstart their careers as future business leaders.
  • MedAxiom and Wharton Online also developed Cardiovascular Business and Management Essentials , a novel blended asynchronous and synchronous program designed for mid-career cardiovascular professionals.

American College of Cardiology Program to Increase Cholesterol Screenings

Retrieved on: 
Tuesday, September 12, 2023
ACC, Amgen, College, Cardiovascular disease, American Heart Association, American College of Cardiology, Registry, Cholesterol, Stroke, MACC, FACC, NCDR, Woman, Multimedia, Improvement, Doctor of Philosophy, Health policy, Practice Fusion, Science, Outline, ECDP, Guideline, Patient, Risk, Practice management, LDL, Knowledge, ASCVD, Moyamoya disease, American College, Health, Medical device, Pharmaceutical industry, Nursing, Esperies, MD, Cardiology

WASHINGTON, Sept. 12, 2023 /PRNewswire/ -- The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, "Driving Urgency in LDL Screening," to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular disease to help clinicians identify those who need treatment in accordance with medical guidelines.

Key Points: 
  • The higher a person's LDL, or "bad" cholesterol, the higher the chance of developing heart disease or having a heart attack or stroke.
  • Evidence has shown that lowering LDL levels through lifestyle changes and/or medications can reduce a person's risk of atherosclerotic cardiovascular disease (ASCVD).
  • We are proud to have joined forces with the American College of Cardiology and Esperion on this collaborative effort to increase doctor-directed screening and, ultimately, helping to improve cardiovascular care and patient outcomes."
  • The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all.

RhythmScience Announces Formation of Medical Advisory Board

Retrieved on: 
Thursday, August 31, 2023
Torrance Memorial Medical Center, FHRS, Heart failure, Heart, FACC, Cardiac electrophysiology, Patient, SAN, University, Cardiology, MPH, MAB, Medical device, Hospital, MD

SAN FRANCISCO, Aug. 31, 2023 /PRNewswire/ -- RhythmScience, a leader in cardiac data management and services, today announced the formation of its Medical Advisory Board (MAB).

Key Points: 
  • SAN FRANCISCO, Aug. 31, 2023 /PRNewswire/ -- RhythmScience, a leader in cardiac data management and services, today announced the formation of its Medical Advisory Board (MAB).
  • "We selected MAB members across a range of cardiology expertise, and we are excited to work with this esteemed group."
  • said Shawn Kumar, CEO of RhythmScience.
  • With their collective knowledge and expertise, we are confident in our ability to positively impact the future of cardiac care."

Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

Retrieved on: 
Friday, August 25, 2023
Biotechnology, General Health, Health, Pharmaceutical, Cardiology, Ochsner Health System, Bleeding, Pfizer, Senior, Trial of the century, Stroke, FACP, PFE, FACC, RVT, NVAF, European Society of Cardiology, Bristol Myers Squibb, PSM, Medicine, Pharmacy, Data mart, Congress, Anticoagulant, Hospital medicine, MMM, Patient, Risk, Causality, Rivaroxaban, Confidence interval, Clutch (eggs), BMS, ESC, Safety, Pharmaceutical industry, Medical imaging, Apixaban, MB, Ventricular fibrillation, ATHENS, MD

There were 167,868 Eliquis initiators and 65,888 rivaroxaban initiators who met study criteria.

Key Points: 
  • There were 167,868 Eliquis initiators and 65,888 rivaroxaban initiators who met study criteria.
  • It is important to note that anticoagulants, including Eliquis, increase the risk of bleeding and can cause serious, potentially fatal bleeding.
  • Additionally, reasons for switching are not known and sample size for those who switched is much lower than those who continued treatment.
  • Due to these limitations, real-world data analyses are not used as evidence to validate the efficacy and/or safety of a treatment.

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

Retrieved on: 
Monday, August 21, 2023
Aurora, University, CET, Heart failure, Chronic kidney disease, ESC Congress, MI, Hospital, FACC, Anschutz Medical Campus, Trial of the century, CO, Patient, Risk, School, Type, ESC, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Lexicon, Pharmaceutical industry, Dietary supplement

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns of heart failure diagnoses, will be highlighted in two sessions during ESC Congress 2023, taking place August 25-28, 2023, in Amsterdam, The Netherlands and online.

Key Points: 
  • THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns of heart failure diagnoses, will be highlighted in two sessions during ESC Congress 2023, taking place August 25-28, 2023, in Amsterdam, The Netherlands and online.
  • On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
    type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
  • Details of the two presentations are as follows:
    Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF – an oral presentation, Saturday, August 26, 4:00 – 4:10 p.m. CET, RAI Amsterdam Convention Center, Science Box 2 and online, presented by Bertram Pitt, M.D., FACC, professor of medicine emeritus at the University of Michigan, School of Medicine, Ann Arbor, MI
    Temporal shift in heart failure diagnoses among hospitalized patients within a large US integrated health system – a moderated ePoster presentation, Saturday, August 26, 2:45 – 2:50 p.m. CET, RAI Amsterdam Convention Center, Station 3 and online, presented by Marc Bonaca, M.D., M.P.H., University of Colorado Anschutz Medical Campus, Aurora, CO

The Inner Circle Acknowledges, Stephen L. Moore as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Osteopathic Medicine

Retrieved on: 
Monday, August 21, 2023
Heart, Mount Clemens, Michigan, Cardiac electrophysiology, Bachelor, Travel, Osteopathic medicine in the United States, University, FHRS, Education, Internal medicine, American College of Cardiology, Professional, AOBIM, Cardiovascular disease, FACC, Patient, Inner circle, American Osteopathic Board of Internal Medicine, Cooking, Cleveland Clinic, EP, Doctor of Osteopathic Medicine, Bachelor's degree, Acute decompensated heart failure, AVON, Defibrillation, Cardiology, American College, Women's Choice Awards, Triple, Family, Disease, Nursing, Medical device

AVON LAKE, Ohio, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephen L. Moore is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Osteopathic Medicine.

Key Points: 
  • AVON LAKE, Ohio, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephen L. Moore is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Osteopathic Medicine.
  • Dr. Moore pursued higher education at the University of Mississippi where he earned a Bachelor's Degree.
  • He then attended Kansas City University of Medicine and Biosciences College of Osteopathic Medicine where he received a Doctor of Osteopathic Medicine degree.
  • Aside from his professional pursuits, Dr. Moore enjoys spending time with his family, cooking, and travel.

Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring

Retrieved on: 
Wednesday, August 16, 2023
Heart, Cardiac electrophysiology, TRINITY, Partnership, Education, Acute coronary syndrome, Cardiovascular disease, FACC, Fear, Splenic infarction, Consultant, Quality of life, DRS, Cardiology, Hospital, Acquisition, Patient, Physician, Risk, Transaction, Korea Disease Control and Prevention Agency, FACS, FDA, Death, World Health Organization, Medical device, Pharmaceutical industry, Guardian, Tampa Bay, MD

EATONTOWN, N.J. and TRINITY, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and the Heart & Rhythm Institute of Trinity, an ambulatory surgery center created by ten of the top cardiologists in the Tampa Bay area, announced today they have entered into an agreement to make the Guardian™ System, the first and only FDA-approved implantable heart attack detection and warning system, available to the Heart & Rhythm Institute of Trinity and its collaborative group of cardiologists who work across seven cardiology practices and serve seven hospitals in the area. This partnership seeks to enhance the Heart & Rhythm Institute’s commitment to redefining the future of cardiac care with cutting-edge technology.

Key Points: 
  • This partnership seeks to enhance the Heart & Rhythm Institute’s commitment to redefining the future of cardiac care with cutting-edge technology.
  • Avertix’s Guardian System is designed to detect acute coronary syndrome events, such as heart attacks—even silent and atypical symptomatic heart attacks—in real time.
  • The implantable device is designed to continuously capture cardiac signals from inside the heart in order to provide life-saving alerts to patients and healthcare professionals, enabling seamless and personalized cardiac care.
  • “For many cardiac patients, the risk of subsequent heart attacks brings a sense of fear to their lives.

Boston Scientific Receives FDA Approval for the POLARx™ Cryoablation System

Retrieved on: 
Tuesday, August 8, 2023
Heart, Freedom, Pulmonary vein stenosis, Boston Scientific, BSX, Anatomy, CE marking, Medicines and Healthcare products Regulatory Agency, Food and Drug Administration, FACC, Clinical trial, Cryoablation, Cryotherapy, Banner University Medical Center Tucson, Heart Rhythm, Patient, Freezing, Physician, PMDA, AF, FDA, NYSE, Food, Safety, Medical imaging, Medical device, FHRS, MD, Electrophysiology

MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the POLARx™ Cryoablation System. The new system, which is indicated for the treatment of patients with paroxysmal atrial fibrillation (AF), features the POLARx FIT Cryoablation Balloon Catheter, a device with the unique capability of enabling two balloon sizes – 28 and 31mm – in one catheter.

Key Points: 
  • First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems
    MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the POLARx™ Cryoablation System.
  • "The U.S. approval of the POLARx Cryoablation System, which has been used in more than 25,000 patients worldwide to date, marks an exciting advancement for the treatment of AF and a new era of cryoablation capabilities," said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific.
  • The POLARx Cryoablation System received CE Mark in February of 2020 and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval in October of 2021.
  • The POLARx FIT catheter received approval in Europe, Japan, Canada and other Asia Pacific markets in 2023.

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Retrieved on: 
Tuesday, August 8, 2023
University, Heart failure, Journal of the American College of Cardiology, HF, FACC, Research, Mortality, Patient, School, Post hoc analysis, American College, Caregiver, FDA, SGLT, Regulation of tobacco by the U.S. Food and Drug Administration, Food, JACC, Pharmaceutical industry, Journal

THE WOODLANDS, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of data from the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin has been published by the Journal of the American College of Cardiology (JACC): Heart Failure. The U.S. Food and Drug Administration (FDA) approved sotagliflozin under the brand name INPEFATM for treatment of heart failure (HF) on May 26, 2023.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved sotagliflozin under the brand name INPEFA TM for treatment of heart failure (HF) on May 26, 2023.
  • Of the 1,222 randomized patients participating in the SOLOIST-WHF study, 596 received sotagliflozin on or before their date of discharge.
  • Treatment with sotagliflozin resulted in significant relative risk reductions of approximately 50% for readmission for non-fatal heart failure events and for the composite of cardiovascular death and readmission for heart failure at 30- or 90-days following hospital discharge versus placebo.
  • The results emphasize the importance of beginning SGLT inhibition before discharge.”
    “We are grateful to the SOLOIST-WHF investigators for conducting this important analysis.

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Retrieved on: 
Tuesday, August 8, 2023
SAB, Ohio State University, Orchestra, Partnership, Institutional review board, HOPE, Virtue, FACC, ISR, Sirolimus, SABRE, Medicine, Angioplasty, Patient, Christ Hospital, IDE, Coronary artery disease, Principal, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, POBA, Terumo

“We believe that Virtue SAB has the potential to address a significant unmet clinical need and improve outcomes for a patient population with suboptimal treatment options.

Key Points: 
  • “We believe that Virtue SAB has the potential to address a significant unmet clinical need and improve outcomes for a patient population with suboptimal treatment options.
  • “This IDE approval and forthcoming pivotal study reflect our commitment to accelerating innovation through our differentiated, partnership-enabled business model.
  • The Virtue ISR-US pivotal study is a randomized, prospective, double-blind, multi-center, controlled study of Virtue SAB vs.
  • The conditional approval also requires the Company to submit additional information to the FDA.